Why is oral CBD so poorly absorbed, and how can absorption be improved?

Oral CBD has only ~6% bioavailability due to extensive first-pass hepatic metabolism — primarily by CYP3A4 and CYP2C19 — and poor aqueous solubility (CBD is highly lipophilic, logP ~6.3). Most orally ingested CBD is metabolized to 7-hydroxy-CBD and 7-carboxy-CBD before reaching systemic circulation. Strategies to improve absorption: (1) High-fat meals — a high-fat meal increases CBD Cmax by ~5x and AUC by ~4x (FDA data from Epidiolex trials). (2) Sublingual administration — bypasses first-pass metabolism, achieving 35% higher Cmax with faster onset (~45 min vs. 2+ hours). (3) Lipid-based formulations — self-emulsifying drug delivery systems (SEDDS) improve solubilization. (4) Nanoformulations — nanoemulsions and liposomal CBD show improved bioavailability in early studies. (5) Inhalation — 10–35% bioavailability with rapid onset, but respiratory risks. For therapeutic use, sublingual or oral-with-fat is the most practical improvement over standard oral dosing.